G. van Hazel

发表

Cetuximab for the treatment of colorectal cancer.

Dongsheng Tu, John R Zalcberg, R. Simes, 2007, The New England journal of medicine.

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

David Miles, Shailendra Verma, Chris Twelves, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17

P. Gibbs, N. Pavlakis, D. Tu, 2013, Clinical Cancer Research.

Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response.

P. Gibbs, N. Pavlakis, D. Tu, 2018, Current oncology.

Home chemotherapy for cancer patients: cost analysis and safety.

G. van Hazel, G. V. van Hazel, 1997, The Medical journal of Australia.

Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.

V. Gebski, G. van Hazel, J. Anderson, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised phase 2 trial of SIR‐Spheres® plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer

G. van Hazel, G. Cardaci, P. Moroz, 2004, Journal of surgical oncology.

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

V. Gebski, J. Desai, N. Pavlakis, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.

G. M. Briggs, N. Pavlakis, D. Goldstein, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

V. Gebski, J. Simes, D. Cunningham, 2015, British Journal of Cancer.

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.

E. Van Cutsem, P. Ruff, D. Cunningham, 2015, European journal of cancer.

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

V. Gebski, J. Desai, N. Pavlakis, 2016, BMC Cancer.

Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.

P. Gibbs, N. Pavlakis, J. Meharchand, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial

V. Gebski, N. Pavlakis, A. Dobrovic, 2013, British Journal of Cancer.

Oxaliplatin‐induced interstitial lung disease

P. Thompson, M. Millward, G. van Hazel, 2008 .

Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].

V. Gebski, R. Simes, S. Clarke, 2011, European journal of cancer.

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.

W. Scheithauer, C. Twelves, J. Cassidy, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

M. Stockler, V. Gebski, R. Simes, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

M. Stockler, V. Gebski, J. Zalcberg, 2010, British Journal of Cancer.

Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study

V. Gebski, P. Gibbs, Kenneth G. Thurston, 2014, BMC Cancer.

Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies

V. Gebski, P. Gibbs, F. Lammert, 2018, Clinical colorectal cancer.

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

D. Kerr, E. Van Cutsem, D. Cunningham, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of CNS metastases on the survival of patients with small cell cancer of the lung

G. van Hazel, R. Eagan, M. Scott, 1983, Cancer.

Early results from implementation of a ‘watch and wait’ protocol for complete clinical response following chemoradiotherapy for rectal cancer

G. van Hazel, Colin Tang, Colin I. Tang, 2022, ANZ journal of surgery.

Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.

D. Miles, L. Mauriac, J. O’Shaughnessy, 2004, Clinical breast cancer.

Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer

V. Gebski, P. Gibbs, Ricky A. Sharma, 2017, JMIR research protocols.

Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

E. Van Cutsem, E. Raymond, A. Vinik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

REsect: blinded assessment of resectability of previously unresectable colorectal cancer liver metastases following chemotherapy±Y90-RadioEmbolization

P. Gibbs, W. Bechstein, V. Donckier, 2019, HPB.

Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial.

W. Scheithauer, C. Twelves, J. Cassidy, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regression of liver metastases following treatment with yttrium-90 microspheres.

G. van Hazel, M. Burton, J. Anderson, 2010, The Australian and New Zealand journal of surgery.

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.

V. Gebski, P. Gibbs, V. Heinemann, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to E.C. Harrold et al and A.O. Ayoola et al.

P. Gibbs, G. van Hazel, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17.

P. Gibbs, N. Pavlakis, J. Meharchand, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adequate SIRT activity dose is as important as adequate chemotherapy dose - Authors' reply.

P. Gibbs, Ricky A. Sharma, J. Moschandreas, 2017, The Lancet. Oncology.

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab

E. Van Cutsem, Y. Humblet, G. Bodoky, 2007, British Journal of Cancer.

Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE‐global randomised trials of selective internal radiotherapy for metastatic colorectal cancer

P. Gibbs, A. Gray, S. Love, 2019, International journal of cancer.

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.

A. Musk, N. de Klerk, J. Dewar, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer

D. Goldstein, N. Spry, M. Michael, 2007, British Journal of Cancer.

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

E. Van Cutsem, J. Tabernero, P. Ruff, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial

P. Gibbs, W. Bechstein, V. Donckier, 2019, The British journal of surgery.

Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.

P. Gibbs, Ricky A. Sharma, B. Morgan, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine as adjuvant treatment for stage III colon cancer.

Markus Abt, Joseph McKendrick, Marek Pawlicki, 2005, The New England journal of medicine.

The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer

V. Gebski, D. Goldstein, S. Ackland, 2011, British Journal of Cancer.

Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC

S. Srinivas, P. Mainwaring, R. Dreicer, 2010, Clinical Cancer Research.

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

R. Gelber, M. Buyse, A. Goldhirsch, 2008, Journal of the National Cancer Institute.

Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.

J. Kovach, M. O’connell, J. Rubin, 1983, Cancer treatment reports.

Cetuximab Alone or With Irinotecan for Resistant KRAS‐, NRAS‐, BRAF‐ and PIK3CA‐wild‐type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study

V. Gebski, J. Desai, N. Pavlakis, 2018, Clinical colorectal cancer.

Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma

P. Gibbs, L. Lipton, M. Lichtenstein, 2015, BMC Cancer.

Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial.

V. Gebski, G. van Hazel, M. Byrne, 1989, British Journal of Cancer.

Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

Val Gebski, Diana Zannino, M. Stockler, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer

P. Gibbs, G. van Hazel, A. Hatswell, 2017, Journal of medical economics.

Adjuvant immunotherapy with BCG in stage II malignant melanoma

G. van Hazel, C. Holman, M. Byrne, 1983, Journal of surgical oncology.

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

W. Scheithauer, J. Zaluski, H. Burris, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

E. Van Cutsem, J. Tabernero, P. Ruff, 2014, European journal of cancer.

Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine.

J. Rubin, G. van Hazel, C. Moertel, 1983, Cancer treatment reports.

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

P. Philip, M. Mahoney, H. Pitot, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311

J. Forbes, V. Gebski, R. Simes, 2019, Breast Cancer Research and Treatment.

Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non‐small cell lung cancer

J. Dewar, N. Spry, G. van Hazel, 2005, Internal medicine journal.

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.

R. Simes, A. Broad, V. Ganju, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA-006Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line therapy.

P. Gibbs, V. Heinemann, M. Peeters, 2017, Annals of Oncology.

Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line therapy.

P. Gibbs, V. Heinemann, M. Peeters, 2017, Annals of Oncology.

Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.

A. Musk, J. Upham, G. van Hazel, 1993, Australian and New Zealand journal of medicine.

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.

E. Van Cutsem, P. Ruff, G. van Hazel, 2018, Journal of geriatric oncology.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

V. Gebski, P. Gibbs, F. Lammert, 2017, The Lancet. Oncology.

Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume

G. van Hazel, P. Moroz, B. Gray, 2001, Journal of surgical oncology.

Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.

G. van Hazel, C. Cheah, D. Spagnolo, 2019, European Journal of Cancer.